

CORPORATE PROFILE


Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Since its introduction, the BVA-100 Blood Volume Analyzer has been used in over 40,000 clinical cases and numerous research studies highlighting its potential to transform therapy. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions including heart failure and critical care by better informing treatment strategies, resulting in significantly better patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients.

350 Fifth Ave., Suite 4740
New York, NY 10118
Phone: 212-330-8500
<http://www.daxor.com>
info@daxor.com

Bret Shapiro
CORE IR
377 Oak Street
Garden City, NY 11530
Phone: 516-222-2560
E-mail: brets@coreir.com
www.coreir.com

STOCK PERFORMANCE

Symbol	DXR
Exchange	AMX
Market Cap.	49.93m
52 Week Range	7.77 - 17.90
Close	13.48
Volume	5
Shares Outstanding	3,888,710
As of Jun 26, 2020 8:00 pm	



MANAGEMENT TEAM

Michael Feldschuh - CEO and President

Robert Michel - Chief Financial Officer

Jonathan Feldschuh - Chief Scientific Officer

Soren Thompson - VP Business Development

Kathryn A. Kornafel - Vice President Marketing & Commercial Development

BOARD OF DIRECTORS

Michael R. Feldschuh - Director

James A. Lombard - Director

Martin S. Wolpoff - Director

Edward S. Feuer - Director

Bernhard Saxe - Director

Jonathan Feldschuh - Chief Scientific Officer

RECENT HEADLINES

[May 28, 2020 - Form NPORT-P](#)

[May 26, 2020 - Daxor Corporation, CEO Michael Feldschuh to Participate in Maxim Group's COVID-19 Virtual Conference on May 27, 2020](#)

[May 22, 2020 - Daxor's BVA-100® Published in Novel Study in American Heart Association Journal - Circulation](#)

[Apr 23, 2020 - Daxor Awarded \\$1.1 Million Contract from United States Department of Defense \(DOD\) for Rapid Portable Blood Volume Analyzer](#)

[Mar 20, 2020 - Daxor Corporation's BVA-100® Test Used to Guide Treatment In COVID-19 Patient](#)

PAST EVENTS

Sep 15, 2018 - Daxor to Exhibit at The 22nd Annual Scientific Meeting of the Heart Failure Society of America